June 13, 2022
Life Sciences
  • Sanofi SA and GSK PLC said a late-stage trial showed their experimental COVID-19 booster shot activated a substantial boost in antibodies against several variants — including omicron BA.1 and BA.2 — compared to its first-generation booster shot. Sanofi and GSK also cited an independent study of 247 people that found that the drugmakers’ experimental shot generated a stronger immune response than both its original booster and the Pfizer-BioNTech booster. (Article here)